Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.
Aguirre LE, Jain A, Ball S, Ali NA, Volpe VO, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Yun S, Kuykendall A, Komrokji R. Aguirre LE, et al. Among authors: padron e. Clin Lymphoma Myeloma Leuk. 2024 Mar 11:S2152-2650(24)00108-3. doi: 10.1016/j.clml.2024.03.001. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38548563
Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant.
Ionescu F, David JC, Ravichandran A, Sallman DA, Sweet K, Komrokji RS, Chan O, Kuykendall A, Padron E, Faramand R, Bejanyan N, Khimani F, Elmariah H, Pidala J, Mishra A, Perez L, Nishihori T, Lancet JE. Ionescu F, et al. Among authors: padron e. Clin Lymphoma Myeloma Leuk. 2024 Feb 12:S2152-2650(24)00064-8. doi: 10.1016/j.clml.2024.02.005. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38429222
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
Jain AG, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji R. Jain AG, et al. Among authors: padron e. Haematologica. 2024 Feb 1. doi: 10.3324/haematol.2023.283661. Online ahead of print. Haematologica. 2024. PMID: 38299605 Free article.
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.
Chan O, Al Ali N, Tashkandi H, Ellis A, Ball S, Grenet J, Hana C, Deutsch Y, Zhang L, Hussaini M, Song J, Yun S, Talati C, Kuykendall A, Padron E, Walker A, Roboz G, Desai P, Sallman D, Sweet K, Komrokji R, Lancet J. Chan O, et al. Among authors: padron e. Blood Adv. 2024 Mar 12;8(5):1075-1083. doi: 10.1182/bloodadvances.2023011173. Blood Adv. 2024. PMID: 38170740 Free PMC article.
260 results